Press releases

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview...

First approval of a dry powder inhaler for treatment of PAH and PH-ILD DPI device represents a convenient option for administration of treprostinil therapy Commercial launch...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31...

Mini-symposia to focus on long-term extension data for the Tyvaso® INCREASE study, the ralinepag phase 2 study, and the Orenitram® FREEDOM-EV studyPoster presentations touch on real-world treprostinil use, Tyvaso DPI™...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its first quarter 2022 financial results before the market opens...

In subjects with PAH, transition from Tyvaso® to Tyvaso DPI™ demonstrated safety and tolerability with significant improvements in six-minute walk distance, device preference and satisfaction, and patient reported...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond, Chief Financial Officer and Treasurer, will provide an overview...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an...

Double-digit percentage revenue and patient count growth in full-year 2021 Company reaffirms target to reach 6,000 patients with Tyvaso by the end of 2022 ...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2021 financial results before...

UKidney™ procedure data published in the American Journal of Transplantation; the first such data published in a peer-reviewed journalUHeart™ recipient patient reaches a two-week milestone post-transplantUThymoKidney™...

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer, and Michael...